The Latest News February 1, 2021 argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis Breda, the Netherlands argenx today announced its plan to continue enrollment in the ADHERE trial evaluating subcutaneous (SC) efgartigimod (co-formulated with Halozyme's ENHANZE® drug-delivery technology) in chronic inflammatory demyelinating polyneuropathy (CIDP). Read argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis More Press Releases News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read News February 5, 2021 argenx announces closing of global offering argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary... Read News February 4, 2021 argenx announces full exercise of underwriters’ option to purchase additional ADSs argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the... Read Media center ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags April 7, 2020 SIMPLE Antibody platform / Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform April 7, 2020 SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics April 7, 2020 SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy April 7, 2020 Cusatuzumab / CD70: An emerging target in cancer immunotherapy April 7, 2020 Cusatuzumab / Phase 1 dose-escalation study of the anti-CD70 antibody ARGX-110 in Advanced Malignancies Load more
News February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update. Read
News February 5, 2021 argenx announces closing of global offering argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary... Read
News February 4, 2021 argenx announces full exercise of underwriters’ option to purchase additional ADSs argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the... Read
